- Home
- DXR vs IFRX Comparison
DXR vs IFRX Comparison
Compare DXR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- IFRX
- Stock Information
- Founded
- DXR 1970
- IFRX 2007
- Country
- DXR United States
- IFRX Germany
- Employees
- DXR N/A
- IFRX N/A
- Industry
- DXR Medical/Dental Instruments
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- IFRX Health Care
- Exchange
- DXR Nasdaq
- IFRX Nasdaq
- Market Cap
- DXR 46.1M
- IFRX 53.5M
- IPO Year
- DXR N/A
- IFRX 2017
- Fundamental
- Price
- DXR $10.14
- IFRX $0.90
- Analyst Decision
- DXR Strong Buy
- IFRX Strong Buy
- Analyst Count
- DXR 1
- IFRX 4
- Target Price
- DXR $25.00
- IFRX $7.75
- AVG Volume (30 Days)
- DXR 3.2K
- IFRX 351.1K
- Earning Date
- DXR 01-01-0001
- IFRX 08-07-2025
- Dividend Yield
- DXR N/A
- IFRX N/A
- EPS Growth
- DXR 86.16
- IFRX N/A
- EPS
- DXR 0.11
- IFRX N/A
- Revenue
- DXR $119,714.00
- IFRX $140,242.00
- Revenue This Year
- DXR N/A
- IFRX N/A
- Revenue Next Year
- DXR N/A
- IFRX $1,276.37
- P/E Ratio
- DXR $92.00
- IFRX N/A
- Revenue Growth
- DXR N/A
- IFRX 30.90
- 52 Week Low
- DXR $6.55
- IFRX $0.71
- 52 Week High
- DXR $10.23
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- DXR 65.31
- IFRX 52.02
- Support Level
- DXR $9.05
- IFRX $0.82
- Resistance Level
- DXR $9.90
- IFRX $0.89
- Average True Range (ATR)
- DXR 0.29
- IFRX 0.06
- MACD
- DXR 0.02
- IFRX 0.01
- Stochastic Oscillator
- DXR 100.00
- IFRX 75.92
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.